These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12474053)

  • 1. Role of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model.
    Gabri MR; Ripoll GV; Alonso DF; Gómez DE
    J Cancer Res Clin Oncol; 2002 Dec; 128(12):669-77. PubMed ID: 12474053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
    Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
    Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma.
    Alonso DF; Gabri MR; Guthmann MD; Fainboim L; Gomez DE
    Int J Oncol; 1999 Jul; 15(1):59-66. PubMed ID: 10375594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.
    Carr A; Mazorra Z; Alonso DF; Mesa C; Valiente O; Gomez DE; Perez R; Fernandez LE
    Melanoma Res; 2001 Jun; 11(3):219-27. PubMed ID: 11468510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo.
    Dohi T; Nores G; Hakomori S
    Cancer Res; 1988 Oct; 48(20):5680-5. PubMed ID: 3167827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.
    Ravindranath MH; Brazeau SM; Morton DL
    Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
    Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen.
    Nores GA; Dohi T; Taniguchi M; Hakomori S
    J Immunol; 1987 Nov; 139(9):3171-6. PubMed ID: 3668254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.
    Labrada M; Clavell M; Bebelagua Y; León Jd; Alonso DF; Gabri MR; Veloso RC; Vérez V; Fernández LE
    Expert Opin Biol Ther; 2010 Feb; 10(2):153-62. PubMed ID: 20088712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.
    Venier C; Guthmann MD; Fernández LE; Fainboim L
    Clin Exp Immunol; 2007 Feb; 147(2):379-88. PubMed ID: 17223981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
    Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
    J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
    Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of melanoma antigen and its involvement in tumor-escape mechanisms.
    Taniguchi M; Sakatsume M; Harada Y; Nores GA; Hakomori S
    Princess Takamatsu Symp; 1988; 19():247-54. PubMed ID: 2978619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.
    Ravindranath MH; Kelley MC; Jones RC; Amiri AA; Bauer PM; Morton DL
    Int J Cancer; 1998 Jan; 75(1):117-24. PubMed ID: 9426699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthetase, on expression of cell surface glycolipid antigen and binding to adhesive proteins by B16 melanoma cells.
    Inokuchi J; Momosaki K; Shimeno H; Nagamatsu A; Radin NS
    J Cell Physiol; 1989 Dec; 141(3):573-83. PubMed ID: 2531751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.
    Mazorra Z; Mesa C; Fernández A; Fernández LE
    Cancer Immunol Immunother; 2008 Dec; 57(12):1771-80. PubMed ID: 18351335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
    J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of sialidase activity and G(M3) content in B16 melanoma variants with different metastatic potential.
    Sawada M; Moriya S; Shineha R; Satomi S; Miyagi T
    Acta Biochim Pol; 1998; 45(2):343-9. PubMed ID: 9821865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.